-
1
-
-
0030893779
-
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2, BRCA1, BRCA2
-
Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2, BRCA1, BRCA2. JAMA. 1997;277:997-1003.
-
(1997)
JAMA
, vol.277
, pp. 997-1003
-
-
Burke, W.1
Daly, M.2
Garber, J.3
-
2
-
-
0037878019
-
Best clinical practices
-
Executive Committee and Panel, ed. Rockville, Md: US Dept of Health and Human Services
-
Executive Committee and Panel. Best clinical practices. In: Executive Committee and Panel, ed. Women's Health and Menopause: A Comprehensive Approach. Rockville, Md: US Dept of Health and Human Services; 2002:1-28.
-
(2002)
Women's Health and Menopause: A Comprehensive Approach
, pp. 1-28
-
-
-
3
-
-
0032528265
-
The concise handbook of family cancer syndromes
-
Lindor N, Greene M, for the Mayo Familial Cancer Program. The concise handbook of family cancer syndromes. J Natl Cancer Inst. 1998; 90:1039-1071.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1039-1071
-
-
Lindor, N.1
Greene, M.2
-
4
-
-
0012742799
-
-
Atlanta, Ga: American Cancer Society Inc.
-
American Cancer Society. Cancer Facts & Figures 2003. Atlanta, Ga: American Cancer Society Inc; 2003.
-
(2003)
Cancer Facts & Figures 2003
-
-
-
6
-
-
0038744296
-
Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected incase series unselected for family history: A combined analysis of 22 studies
-
Antoniou A, Pharoh P, Narod S, et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected incase series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
-
(2003)
Am J Hum Genet
, vol.72
, pp. 1117-1130
-
-
Antoniou, A.1
Pharoh, P.2
Narod, S.3
-
7
-
-
0031832541
-
Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
-
Frank T, Manley S, Olopade O, Cummings S, Garber J. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16(7):2417-2425.
-
(1998)
J Clin Oncol
, vol.16
, Issue.7
, pp. 2417-2425
-
-
Frank, T.1
Manley, S.2
Olopade, O.3
Cummings, S.4
Garber, J.5
-
8
-
-
0033610723
-
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
-
Jernstrom H, Lerman C, Ghadirian P, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;354(9193): 1846-1850.
-
(1999)
Lancet
, vol.354
, Issue.9193
, pp. 1846-1850
-
-
Jernstrom, H.1
Lerman, C.2
Ghadirian, P.3
-
9
-
-
0033668796
-
Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer
-
Pike M, Ross R. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000;65:659-664.
-
(2000)
Steroids
, vol.65
, pp. 659-664
-
-
Pike, M.1
Ross, R.2
-
10
-
-
0029056755
-
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
-
Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589-1593.
-
(1995)
N Engl J Med
, vol.332
, Issue.24
, pp. 1589-1593
-
-
Colditz, G.A.1
Hankinson, S.E.2
Hunter, D.J.3
-
11
-
-
0032547326
-
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
-
Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
-
(1998)
JAMA
, vol.280
, pp. 605-613
-
-
Hulley, S.1
Grady, D.2
Bush, T.3
-
12
-
-
0034640040
-
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
-
Shilpak MG, Grady D, Bush T, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
-
(2000)
JAMA
, vol.283
, pp. 1845-1852
-
-
Shilpak, M.G.1
Grady, D.2
Bush, T.3
-
13
-
-
0037014584
-
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II)
-
Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49-57.
-
(2002)
JAMA
, vol.288
, pp. 49-57
-
-
Grady, D.1
Herrington, D.2
Bittner, V.3
-
14
-
-
0037014630
-
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II)
-
Hulley S, Fulberg C, Barrett Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:58-66.
-
(2002)
JAMA
, vol.288
, pp. 58-66
-
-
Hulley, S.1
Fulberg, C.2
Barrett Connor, E.3
-
15
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women
-
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333.
-
(2002)
JAMA
, vol.288
, Issue.3
, pp. 321-333
-
-
-
16
-
-
0036569877
-
The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
-
Lakhani S, van der Vijver MJ, Jacqueneir J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9): 2310-2318.
-
(2002)
J Clin Oncol
, vol.20
, Issue.9
, pp. 2310-2318
-
-
Lakhani, S.1
Van Der Vijver, M.J.2
Jacqueneir, J.3
-
17
-
-
0035219808
-
Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: Computed efficacy, effectiveness and impact
-
Eisinger F, Charafe-Jauffret E, Jacqueneir J, et al. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact. Int J Oncol. 2001;18:5-10.
-
(2001)
Int J Oncol
, vol.18
, pp. 5-10
-
-
Eisinger, F.1
Charafe-Jauffret, E.2
Jacqueneir, J.3
-
18
-
-
0035861037
-
Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2
-
King M, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA. 2001;286(18): 2251-2256.
-
(2001)
JAMA
, vol.286
, Issue.18
, pp. 2251-2256
-
-
King, M.1
-
19
-
-
0034329366
-
Are BRCA1 and BRCA2 associated breast cancers different? Prognosis of BRCA1 associated breast cancer
-
Robson M. Are BRCA1 and BRCA2 associated breast cancers different? Prognosis of BRCA1 associated breast cancer. J Clin Oncol. 2000; 18(21S):113S-118S.
-
(2000)
J Clin Oncol
, vol.18
, Issue.21 S
-
-
Robson, M.1
-
20
-
-
0034331177
-
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
-
Verhoog L, Berns E, Brekelmans C, et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol. 2000;18(21S):119S-124S.
-
(2000)
J Clin Oncol
, vol.18
, Issue.21 S
-
-
Verhoog, L.1
Berns, E.2
Brekelmans, C.3
-
21
-
-
0037148435
-
Estimates of the likely prophylactic effect of tamoxifen in women with high-risk BRCA1 and BRCA2 mutations
-
Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high-risk BRCA1 and BRCA2 mutations. Br J Cancer. 2002;86:218-221.
-
(2002)
Br J Cancer
, vol.86
, pp. 218-221
-
-
Duffy, S.W.1
Nixon, R.M.2
-
22
-
-
0034597916
-
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
-
Narod S, Brunet J, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876-1881.
-
(2000)
Lancet
, vol.356
, pp. 1876-1881
-
-
Narod, S.1
Brunet, J.2
Ghadirian, P.3
-
23
-
-
0034331054
-
Chemoprevention options for BRCA1 and BRCA2 mutation carriers
-
Eeles R, Powles T. Chemoprevention options for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000;18(21S):93S-99S.
-
(2000)
J Clin Oncol
, vol.18
, Issue.21 S
-
-
Eeles, R.1
Powles, T.2
-
24
-
-
0032514413
-
Oral contraceptives and the risk of hereditary ovarian cancer
-
Narod S, Risch H, Moslehr R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339(7):424-428.
-
(1998)
N Engl J Med
, vol.339
, Issue.7
, pp. 424-428
-
-
Narod, S.1
Risch, H.2
Moslehr, R.3
-
26
-
-
0034255545
-
Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives
-
Ness R, Grisso J, Klapper J. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152(3):233-241.
-
(2000)
Am J Epidemiol
, vol.152
, Issue.3
, pp. 233-241
-
-
Ness, R.1
Grisso, J.2
Klapper, J.3
-
27
-
-
0035954651
-
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
-
Modan B, Hartage P, Hirsch-Vechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New Engl J Med. 2001;345(4):235-240.
-
(2001)
New Engl J Med
, vol.345
, Issue.4
, pp. 235-240
-
-
Modan, B.1
Hartage, P.2
Hirsch-Vechezkel, G.3
-
28
-
-
0035849283
-
Tubal ligation and risk of ovarian cancer in carriers for BRCA1 or BRCA2 mutations: A case control study
-
Narod S, Ping S, Sun P, et al. Tubal ligation and risk of ovarian cancer in carriers for BRCA1 or BRCA2 mutations: a case control study. Lancet. 2001;357:1467-1470.
-
(2001)
Lancet
, vol.357
, pp. 1467-1470
-
-
Narod, S.1
Ping, S.2
Sun, P.3
-
29
-
-
0034638446
-
Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer
-
Gabrick D, Hartmann L, Cerhan J, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000;284(14):1791-1798.
-
(2000)
JAMA
, vol.284
, Issue.14
, pp. 1791-1798
-
-
Gabrick, D.1
Hartmann, L.2
Cerhan, J.3
-
30
-
-
0030865837
-
Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
-
Ursin G, Henderson B, Haile R, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 1997;57:3678-3681.
-
(1997)
Cancer Res
, vol.57
, pp. 3678-3681
-
-
Ursin, G.1
Henderson, B.2
Haile, R.3
-
31
-
-
0037021659
-
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
-
Narod S, Dube M, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. JNCI. 2002;94(23): 1773-1779.
-
(2002)
JNCI
, vol.94
, Issue.23
, pp. 1773-1779
-
-
Narod, S.1
Dube, M.2
Klijn, J.3
-
32
-
-
0019960002
-
Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families
-
Tobacman J, Tucker M, Kase R, Greene M, Costa J, Fraumeni J. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;2:795-797.
-
(1982)
Lancet
, vol.2
, pp. 795-797
-
-
Tobacman, J.1
Tucker, M.2
Kase, R.3
Greene, M.4
Costa, J.5
Fraumeni, J.6
-
33
-
-
0027483251
-
Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer
-
Piver M, Jishi M, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer. 1993;71:2751-2755.
-
(1993)
Cancer
, vol.71
, pp. 2751-2755
-
-
Piver, M.1
Jishi, M.2
Tsukada, Y.3
Nava, G.4
-
34
-
-
0029441577
-
Prophylactic oophorectomy in inherited breast/ovarian cancer families
-
Struewing J, Watson P, Easton D, Ponder B, Lynch H, Tucker M. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 1995;17:33-35.
-
(1995)
J Natl Cancer Inst Monogr
, vol.17
, pp. 33-35
-
-
Struewing, J.1
Watson, P.2
Easton, D.3
Ponder, B.4
Lynch, H.5
Tucker, M.6
-
35
-
-
0001771124
-
Ovarian cancer risk reduction after Bilateral Prophylactic Oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers
-
Weber B, Punzalan C, Eisen A, et al. Ovarian cancer risk reduction after Bilateral Prophylactic Oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers [abstract]. Am Soc Hum Genet. 2000;251:59.
-
(2000)
Am Soc Hum Genet
, vol.251
, pp. 59
-
-
Weber, B.1
Punzalan, C.2
Eisen, A.3
-
36
-
-
0031938628
-
Prophylactic oophorectomy in colorectal carcinoma: Preliminary results of a randomized trial
-
Young-Fadok T, Wolff B, Nivatvongs S, Metzger P, Ilstrup D. Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized trial. Dis Colon Rectum. 1998;41(3):277-285.
-
(1998)
Dis Colon Rectum
, vol.41
, Issue.3
, pp. 277-285
-
-
Young-Fadok, T.1
Wolff, B.2
Nivatvongs, S.3
Metzger, P.4
Ilstrup, D.5
-
37
-
-
0037162115
-
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
-
Kauff N, Satagopan J, Bobson M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med. 2002;346(21):1609-1615.
-
(2002)
New Engl J Med
, vol.346
, Issue.21
, pp. 1609-1615
-
-
Kauff, N.1
Satagopan, J.2
Bobson, M.3
-
38
-
-
0037162110
-
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
-
Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med. 2002;346(21): 1616-1622.
-
(2002)
New Engl J Med
, vol.346
, Issue.21
, pp. 1616-1622
-
-
Rebbeck, T.1
Lynch, H.2
Neuhausen, S.3
-
39
-
-
0028801693
-
Ovarian cancer: Screening, treatment, and follow-up
-
NCI Consensus Conference/NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA. 1995;273(6):491-497.
-
(1995)
JAMA
, vol.273
, Issue.6
, pp. 491-497
-
-
-
40
-
-
0032478961
-
Primary peritoneal carcinoma can have multifocal origins: Implications for prophylactic oophorectomy
-
Eisen A, Weber B. Primary peritoneal carcinoma can have multifocal origins: implications for prophylactic oophorectomy. J Natl Cancer Inst. 1998;90(11):797-799.
-
(1998)
J Natl Cancer Inst
, vol.90
, Issue.11
, pp. 797-799
-
-
Eisen, A.1
Weber, B.2
-
41
-
-
0027074247
-
Papillary peritoneal carcinomatosis after prophylactic oophorectomy
-
Kemp G, Hsiu J, Andrews M. Papillary peritoneal carcinomatosis after prophylactic oophorectomy. Gynecol Oncol. 1992;47:395-397.
-
(1992)
Gynecol Oncol
, vol.47
, pp. 395-397
-
-
Kemp, G.1
Hsiu, J.2
Andrews, M.3
-
42
-
-
0033942547
-
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy
-
Lu K, Garber J, Cramet D, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18(14):2728-2732.
-
(2000)
J Clin Oncol
, vol.18
, Issue.14
, pp. 2728-2732
-
-
Lu, K.1
Garber, J.2
Cramet, D.3
-
43
-
-
0033944968
-
Prophylactic oophorectomy: Clinical considerations
-
Gotlieb W, Baruch G, Friedman E. Prophylactic oophorectomy: clinical considerations. Semin Surg Oncol. 2000;19:20-27.
-
(2000)
Semin Surg Oncol
, vol.19
, pp. 20-27
-
-
Gotlieb, W.1
Baruch, G.2
Friedman, E.3
-
44
-
-
0031817420
-
Prophylactic oophorectomy: A continuing controversy
-
Fong Y, Lim F, Arulkumaran S. Prophylactic oophorectomy: a continuing controversy. Obstet Gynecol Surv. 1998;53(8):493-498.
-
(1998)
Obstet Gynecol Surv
, vol.53
, Issue.8
, pp. 493-498
-
-
Fong, Y.1
Lim, F.2
Arulkumaran, S.3
-
45
-
-
0033199603
-
Bad news/good news: Information about breast cancer risk following prophylactic oophorectomy
-
Helzlsouer K. Bad news/good news: information about breast cancer risk following prophylactic oophorectomy. J Natl Cancer Inst. 1999;91(17): 1442-1443.
-
(1999)
J Natl Cancer Inst
, vol.91
, Issue.17
, pp. 1442-1443
-
-
Helzlsouer, K.1
-
46
-
-
0033408439
-
Managing hereditary ovarian cancer risk
-
Berchuck A, Schildkraut J, Marks J, Futreal P. Managing hereditary ovarian cancer risk. Cancer. 1999;86(11):2517-2524.
-
(1999)
Cancer
, vol.86
, Issue.11
, pp. 2517-2524
-
-
Berchuck, A.1
Schildkraut, J.2
Marks, J.3
Futreal, P.4
-
47
-
-
0033199926
-
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
-
Rebbeck T, Levin A, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475-1479.
-
(1999)
J Natl Cancer Inst
, vol.91
, Issue.17
, pp. 1475-1479
-
-
Rebbeck, T.1
Levin, A.2
Eisen, A.3
-
48
-
-
0034331055
-
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
-
Rebbeck T. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000;18(21s):100s-103s.
-
(2000)
J Clin Oncol
, vol.18
, Issue.21 S
-
-
Rebbeck, T.1
-
49
-
-
0035819530
-
Prophylactic oophorectomy in the genome age: Balancing new data against uncertainties
-
Newman L. Prophylactic oophorectomy in the genome age: balancing new data against uncertainties. J Natl Cancer Inst. 2001;93(3):173-175.
-
(2001)
J Natl Cancer Inst
, vol.93
, Issue.3
, pp. 173-175
-
-
Newman, L.1
-
50
-
-
0030590570
-
Prophylactic cancer surgeries offer no guarantees, uncertain outcomes
-
Holzman D. Prophylactic cancer surgeries offer no guarantees, uncertain outcomes. J Natl Cancer Inst. 1996;88(20):1428-1427.
-
(1996)
J Natl Cancer Inst
, vol.88
, Issue.20
, pp. 1428-1427
-
-
Holzman, D.1
-
51
-
-
0037093059
-
Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis
-
Grann V, Jacobson J, Thomason D, Hershman D, Heitjan D, Neugut A. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol. 2002;20(10):2520-2529.
-
(2002)
J Clin Oncol
, vol.20
, Issue.10
, pp. 2520-2529
-
-
Grann, V.1
Jacobson, J.2
Thomason, D.3
Hershman, D.4
Heitjan, D.5
Neugut, A.6
-
52
-
-
0033452876
-
Prophylactic mastectomy and inherited predisposition to breast cancer
-
Hughes K, Papa M, Whitney T, McLellan R. Prophylactic mastectomy and inherited predisposition to breast cancer. Cancer. 1999;86(11): 2502-2516.
-
(1999)
Cancer
, vol.86
, Issue.11
, pp. 2502-2516
-
-
Hughes, K.1
Papa, M.2
Whitney, T.3
McLellan, R.4
-
53
-
-
0033552904
-
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
-
Hartmann L, Schaid D, Woods J, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84.
-
(1999)
N Engl J Med
, vol.340
, Issue.2
, pp. 77-84
-
-
Hartmann, L.1
Schaid, D.2
Woods, J.3
-
54
-
-
0034101299
-
Prophylactic mastectomy: Evolving perspectives
-
Sakorafas G, Tsiotou A. Prophylactic mastectomy: evolving perspectives. Eur J Cancer. 2000;36:567-578.
-
(2000)
Eur J Cancer
, vol.36
, pp. 567-578
-
-
Sakorafas, G.1
Tsiotou, A.2
-
55
-
-
0034691671
-
Reducing the risk of breast cancer
-
Chlebowski R. Reducing the risk of breast cancer. N Engl J Med. 2000; 343(3):191-198.
-
(2000)
N Engl J Med
, vol.343
, Issue.3
, pp. 191-198
-
-
Chlebowski, R.1
-
56
-
-
0034042020
-
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer
-
Kuschel B, Lux M, Goecke T, Beckmann M. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev. 2000;9:139-150.
-
(2000)
Eur J Cancer Prev
, vol.9
, pp. 139-150
-
-
Kuschel, B.1
Lux, M.2
Goecke, T.3
Beckmann, M.4
-
57
-
-
0035478195
-
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer
-
McDonnell S, Schaid D, Myers J, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19(19):3938-3943.
-
(2001)
J Clin Oncol
, vol.19
, Issue.19
, pp. 3938-3943
-
-
McDonnell, S.1
Schaid, D.2
Myers, J.3
-
58
-
-
0035913275
-
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
-
Meijers-Heijboer H, Van Geel B, Van Putten W, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164.
-
(2001)
N Engl J Med
, vol.345
, Issue.3
, pp. 159-164
-
-
Meijers-Heijboer, H.1
Van Geel, B.2
Van Putten, W.3
-
59
-
-
0035913276
-
Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations-facts and controversy
-
Eisen A, Weber B. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations-facts and controversy. N Engl J Med. 2001; 345(3):207-208.
-
(2001)
N Engl J Med
, vol.345
, Issue.3
, pp. 207-208
-
-
Eisen, A.1
Weber, B.2
-
60
-
-
0347249941
-
Position statement on prophylactic mastectomy
-
Society of Surgical Oncology. 2001. Position statement on prophylactic mastectomy. Society Surg Oncol. Available at www.surgonc.org. Accessed August 2001.
-
(2001)
Society Surg Oncol
-
-
-
61
-
-
0030909527
-
Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations
-
Schrag D, Kuntz K, Garber J, Weeks J. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997; 336(20):1465-1471.
-
(1997)
N Engl J Med
, vol.336
, Issue.20
, pp. 1465-1471
-
-
Schrag, D.1
Kuntz, K.2
Garber, J.3
Weeks, J.4
-
62
-
-
0034124104
-
Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery
-
Kuerer H, Hwang S, Anthony J, et al. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol. 2000;7(5):325-332.
-
(2000)
Ann Surg Oncol
, vol.7
, Issue.5
, pp. 325-332
-
-
Kuerer, H.1
Hwang, S.2
Anthony, J.3
-
63
-
-
0001259749
-
NCCN practice guidelines: Genetics/familial high-risk cancer screenings
-
Daly M. NCCN practice guidelines: genetics/familial high-risk cancer screenings. Oncology. 1999;13(11A):161-183.
-
(1999)
Oncology
, vol.13
, Issue.11 A
, pp. 161-183
-
-
Daly, M.1
-
66
-
-
0034090866
-
The management of women at high risk of experiencing hereditary breast and ovarian cancer. The Lahey guidelines
-
Hughes K, Roche C, Whitney T, McLellan R. The management of women at high risk of experiencing hereditary breast and ovarian cancer. The Lahey guidelines. Dis Manage Health Outcomes. 2000;7(4):201-215.
-
(2000)
Dis Manage Health Outcomes
, vol.7
, Issue.4
, pp. 201-215
-
-
Hughes, K.1
Roche, C.2
Whitney, T.3
McLellan, R.4
-
67
-
-
0038715898
-
American Cancer Society guidelines for the breast cancer screening: Update 2003
-
Smith R, Saslow D, Sawyer K, et al. American Cancer Society guidelines for the breast cancer screening: update 2003. CA Cancer J Clin. 2003;53(3):141-169.
-
(2003)
CA Cancer J Clin
, vol.53
, Issue.3
, pp. 141-169
-
-
Smith, R.1
Saslow, D.2
Sawyer, K.3
-
68
-
-
0038501057
-
American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility
-
American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):1-10.
-
(2003)
J Clin Oncol
, vol.21
, Issue.12
, pp. 1-10
-
-
-
69
-
-
0029926091
-
Tamoxifen and endometrial cancer
-
American College of Obstetrics and Gynecologists Committee on Gynecologic Practice. Tamoxifen and endometrial cancer. Int J Gynecol Obstet. 1996;53:197-199.
-
(1996)
Int J Gynecol Obstet
, vol.53
, pp. 197-199
-
-
|